AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06205030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-diabetic herbal drug
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Study NCT06132867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablet
Study NCT05103176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
Study NCT05103176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Object directed grasping
Description: Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action.
Study NCT06627699 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
Study NCT05674513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
Study NCT06742827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention based on information and communication technologies.
Description: will be carried out through a mobile application, which will be installed on each person's device, as well as short text messages will be sent and counseling will be available 24/7. The contents of the application will be educational and will be elaborated framed in the following components: understanding of the disease and the consequences of not adhering (comprehensibility) to the treatment, maintaining a balance between the psychosocial resources that the patient has and the demands that the disease places on them (manageability), and the involvement of the person in decision making and the sense of continuing to adhere to hemodialysis treatment (meaningfulness).
Study NCT06742255 — intervention group
Intervention type: DRUG
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block is an injection of local anesthetic at the level of the neck to target the stellate ganglion, a sympathetic ganglion to interrupt abnormal autonomically-mediated pain in patients resistant to medical treatment
Study NCT05598320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
Study NCT05598320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TransCon CNP
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
Study NCT06253533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICVAX
Description: ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
Study NCT06253533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
Study NCT05603741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.9% Sodium Chloride Injection
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study NCT05603741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Injection 2%
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study NCT06531421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Equity Report Cards
Description: At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
Study NCT04814095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QOL
Description: QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
Study NCT04814095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT imaging
Description: CT radiographic imaging every 12 weeks +/- 2 weeks
Study NCT06206226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHDC-DC
Description: 90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
Study NCT06107634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastropexy
Description: In the intervention group, a three-point gastropexy is added to the repair. First, the right fundus flap is adapted posteriorly to the crural portion of the diaphragm with a 2-3 cm long running non-absorbable suture (posterior gastropexy). Second, the left fundus flap is adapted to the diaphragm anterolateral to the hiatus with a 2-3 cm long running non-absorbable suture (left anterolateral gastropexy). Finally, the minor curvature of the anterior stomach wall is adapted during reduced intraabdominal pressure to the anterior abdominal wall with a 2-3 cm long running non-absorbable suture (anterior gastropexy).
Study NCT06107634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paraesophageal hernia repair
Description: Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
Study NCT06107634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraesophageal hernia repair
Description: Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
Study NCT06465810 — intervention group
Intervention type: DRUG
Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Description: Data will be collected on patients with ATTR amyloidosis in a real-world setting
Study NCT05078970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention+ (SPI+)
Description: SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
Study NCT05078970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Description: CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
Study NCT05078970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: This assigned condition tracks the care received in typical circumstances.
Study NCT05041361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
Study NCT05041361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia (WBH)
Description: Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
Study NCT04258917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study withdrawn
Description: Study withdrawn
Study NCT04924920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SIGH
Description: To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
Study NCT04924920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEOT
Description: • The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
Study NCT04924920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: Bolus of fluids of 4 ml/kg given within 10 minutes
Study NCT06272266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)
Description: For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group.
Study NCT06272266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).
Description: Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
Study NCT06272266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)
Description: At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
Study NCT06272266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)
Description: Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
Study NCT04740970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: JNJ-64304500 injection will be administered subcutaneously.
Study NCT04740970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection will be administered subcutaneously.
Study NCT06334822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
Study NCT06334822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
Study NCT06334822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
Study NCT06334822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
Study NCT06334822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients are presented with one or more optional questionnaires (some validated, some bespoke)
Study NCT06334822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients are presented with one or more optional questionnaires (some validated, some bespoke)
Study NCT06334822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device in pharmacy
Description: Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.
Study NCT06334822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt device alerting system
Description: The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
Study NCT04440254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device
Description: Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
Study NCT06307535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Caregivers
Description: MCP-C is a stakeholder-informed, innovative, manualized intervention designed to assist caregivers to connect to a sense of meaning and purpose in life, despite the challenges of caregiving.
Study NCT06307535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy for Caregivers
Description: Standard of care supportive psychotherapy
Study NCT06101641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shellac nail polish application
Description: The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
Study NCT04266275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin C3 Complex
Description: Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Study NCT04266275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Study NCT05737732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Effective Lighting
Description: Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
Study NCT05688384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + Alfentanil
Description: In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.